KalVista Pharmaceuticals, Inc. has appointed Andreas Maetzel, M.D., M.Sc., Ph.D, to the role of Senior Vice President, Medical.
“Andreas Maetzel brings a wealth of experience in HAE and over 25 years of leadership in the pharmaceutical industry, including clinical development, medical and regulatory affairs,” said Andrew Crockett, CEO of KalVista. “I am confident that he will help maximize the potential of our oral plasma kallikrein HAE portfolio as we continue to advance multiple programs into clinical development and develop a best-in-class oral therapy for this disease.”
Dr. Maetzel was most recently Vice President, Global Medical Affairs at BioCryst Pharmaceuticals. Prior to that, he was Vice President, Clinical Development & Regulatory Affairs at Cornerstone Therapeutics Inc. Previously, Dr. Maetzel held a clinical development role at BioCryst, and also positions in strategy consulting and at Amgen. He is a Visiting Scientist, Faculty of Medicine, University Hospital Zurich and Charité Hospital Berlin, and Adjunct Professor, Institute for Health Policy, Management & Evaluation, University of Toronto. Dr. Maetzel obtained both a Ph.D and M.Sc. in Clinical Epidemiology from the University of Toronto and a Dr. med. at the University of Hannover, Germany.
Dr. Maetzel commented, “I am very excited to join KalVista at this juncture, with the Company advancing a portfolio of oral programs for HAE. I believe that the Company’s strategy of taking multiple compounds into clinical development to develop a best-in-class oral therapy for HAE takes full advantage of KalVista’s unique strengths in chemistry and biological understanding of plasma kallikrein. I look forward to working with the team to develop oral therapies for HAE.”
(Source: KalVista)
